IL17A and psoriasis: Furthermore, in two studies including 119 and 346 patients with psoriasis using IL-17 inhibitors, respectively, none was infected with SARS-CoV-2 (54, 55), which an evidence that the use of IL-17 inhibitors in psoriasis could not increase the risk of SARS-CoV-2 infection.